Deep Learning-Based Annotation Transfer between Molecular Imaging Modalities: An Automated Workflow for Multimodal Data Integration.

Journal: Analytical chemistry
Published Date:

Abstract

An ever-increasing array of imaging technologies are being used in the study of complex biological samples, each of which provides complementary, occasionally overlapping information at different length scales and spatial resolutions. It is important to understand the information provided by one technique in the context of the other to achieve a more holistic overview of such complex samples. One way to achieve this is to use annotations from one modality to investigate additional modalities. For microscopy-based techniques, these annotations could be manually generated using digital pathology software or automatically generated by machine learning (including deep learning) methods. Here, we present a generic method for using annotations from one microscopy modality to extract information from complementary modalities. We also present a fast, general, multimodal registration workflow [evaluated on multiple mass spectrometry imaging (MSI) modalities, matrix-assisted laser desorption/ionization, desorption electrospray ionization, and rapid evaporative ionization mass spectrometry] for automatic alignment of complex data sets, demonstrating an order of magnitude speed-up compared to previously published work. To demonstrate the power of the annotation transfer and multimodal registration workflows, we combine MSI, histological staining (such as hematoxylin and eosin), and deep learning (automatic annotation of histology images) to investigate a pancreatic cancer mouse model. Neoplastic pancreatic tissue regions, which were histologically indistinguishable from one another, were observed to be metabolically different. We demonstrate the use of the proposed methods to better understand tumor heterogeneity and the tumor microenvironment by transferring machine learning results freely between the two modalities.

Authors

  • Alan M Race
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Daniel Sutton
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Gregory Hamm
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Gareth Maglennon
    Oncology Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Jennifer P Morton
    Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
  • Nicole Strittmatter
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Andrew Campbell
    Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
  • Owen J Sansom
    Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
  • Yinhai Wang
    Department of Civil and Environmental Engineering, University of Washington, Seattle, Washington, United States of America.
  • Simon T Barry
    Bioscience, Early Oncology, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Zoltan Takáts
    Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, U.K.
  • Richard J A Goodwin
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Josephine Bunch
    Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, U.K.